Tamura, Shigeyuki http://orcid.org/0000-0002-1116-5586
Taniguchi, Hirokazu
Nishikawa, Kazuhiro
Imamura, Hiroshi
Fujita, Junya
Takeno, Atsushi
Matsuyama, Jin
Kimura, Yutaka
Kawada, Junji
Hirao, Motohiro
Hirota, Masashi
Fujitani, Kazumasa
Kurokawa, Yukinori
Sakai, Daisuke
Kawakami, Hisato
Shimokawa, Toshio
Satoh, Taroh
Clinical trials referenced in this document:
Documents that mention this clinical trial
A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302)
https://doi.org/10.1007/s10147-020-01768-w
Funding for this research was provided by:
Taiho Pharmaceutical
Article History
Received: 31 May 2020
Accepted: 6 August 2020
First Online: 14 September 2020
Compliance with ethical standards
:
: Kazuhiro Nishikawa has received honoraria from Bristol-Myers Squibb, Chugai, EA Pharma, Eli Lilly, Ono, Taiho and Yakult. Hiroshi Imamura has received honoraria from Taiho. Kazumasa Fujitani has received honoraria from Bristol-Myers Squibb, Eli Lilly, Ono, Taiho and Yakult. Yukinori Kurokawa has received honoraria from Taiho, Ono, Eli Lilly, Yakult, Bristol-Myers Squibb, Kaken, Chugai and Takeda, and research funding from Taiho, Ono and MSD. Daisuke Sakai has received honoraria from Chugai and Diichi-Sankyo, and research funding from Chugai, Yakult, Ono, Eli Lilly and Diichi-Sankyo. Hisato Kawakami has received honoraria from Bristol-Myers Squibb. Astra-Zeneca, Bayer Yakuhin, Eli Lilly, MSD, Ono, Chugai, Daiichi Sankyo, Takeda and Taiho, and research funding from Chugai, Taiho and Eisai. Taroh Satoh has received honoraria from Bristol-Myers Squibb, Eli Lilly, Ono, Chugai and Taiho, and research funding from MSD, Gilead, Astellas and Astra-Zeneca, and have received scholarship donations from Taiho, and endowed chairs from Ono, Chugai and Yakult. All remaining authors declare no conflict of interest.